|
|
|
|
|
by labvie
4041 days ago
|
|
The truth is we didn't want to sell to big pharma, they would have shelved likely. Cures don't make profit, treatments do. This is why we wanted to create a company that could put this out to market in less than ten years, get it approved by the FDA as a breakthrough and have it in market in 5 years. Subsidize it to people with need and low income. These are the reasons we felt being in control of the destiny of it was the safest bet. But so far, it seems that the easy way out is to sell it, which would mean it would not become what we want it to be, a cure to various diseases. |
|
This shows that you don't understand the market well.
"Harvoni, made by Gilead Sciences, has cure rates of between 94 and 99 per cent. It is the successor to Gilead’s Sovaldi, which has accrued more than $7bn in US sales since it became available in the final quarter of 2013.
Early data suggest Harvoni is poised to be even more of a success."
http://www.ft.com/cms/s/0/7ac62214-5e1c-11e4-bc04-00144feabd...
Also, the goal of ALL cancer treatments is to cure the cancer (other than maybe slow growing prostate cancers and cancers where there is no cure available and the best you can do is palliative care).